Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTSR1 | P30989 | 2/20 | 0.39 |
| ▸ | PSMB5 | P28074 | 3/20 | 0.36 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.34 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.34 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.34 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.34 |
| ▸ | MMP2 | P08253 | 1/20 | 0.34 |
| ▸ | MMP9 | P14780 | 1/20 | 0.34 |
| ▸ | MMP8 | P22894 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | HTR6 | P50406 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Alanine SCHEMBL601223 | 0.84 | ITGB3 (0.44) | NTSR1PSMB5TSHRSLC40A1KEAP1 | |
| SCHEMBL232948 | 0.82 | ITGB3 (0.45) | NTSR1PSMB5TSHRSLC40A1KEAP1 | |
| Alanine SCHEMBL671385 | 0.79 | PSMB5 (0.46) | PSMB5TSHRMMP2MMP9MMP8 | |
| SCHEMBL2295176 | 0.77 | PSMB5 (0.47) | PSMB5TSHRMMP2MMP9MMP8 | |
| Alanine SCHEMBL15141495 | 0.76 | ALDH1A1 (0.43) | NTSR1TSHRHTTALDH1A1HPGD | |
| Hydrochloric Acid SCHEMBL2297582 | 0.76 | PSMB5 (0.47) | PSMB5TSHRMMP2MMP9MMP8 | |
| Leucine SCHEMBL3814957 | 0.76 | ITGB3 (0.45) | NTSR1TSHRSLC40A1KEAP1NFE2L2 | |
| SCHEMBL901428 | 0.74 | ALDH1A1 (0.44) | NTSR1TSHRHTTALDH1A1HPGD | |
| SCHEMBL1406185 | 0.74 | GAA (0.38) | NTSR1PSMB5TSHRSLC40A1KEAP1 | |
| SCHEMBL7217344 | 0.74 | MAPT (0.53) | NTSR1PSMB5MMP2MMP9ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10953013-B2 | Biomarkers of response to NAE inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2021-03-23 | — | — | US | disclosed |
| US-10662477-B2 | Biomarkers and methods to predict response to inhibitors and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2020-05-26 | — | — | US | disclosed |
| EP-2904115-B1 | BIOMARKERS AND METHODS TO PREDICT RESPONSE TO INHIBITORS AND USES THEREOF | MILLENNIUM PHARM INC (US) | 2018-08-08 | — | — | EP | disclosed |
| EP-2771489-B1 | BIOMARKERS OF RESPONSE TO NAE INHIBITORS | MILLENNIUM PHARM INC (US) | 2018-07-04 | — | — | EP | disclosed |
| US-9920373-B2 | Biomarkers of response to proteasome inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2018-03-20 | — | — | US | disclosed |
| EP-2776586-B1 | BIOMARKERS OF RESPONSE TO PROTEASOME INHIBITORS | MILLENNIUM PHARM INC (US) | 2018-03-07 | — | — | EP | disclosed |
| US-20170105995-A1 | BIOMARKERS OF RESPONSE TO NAE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-04-20 | — | — | US | disclosed |
| US-20160312309-A1 | ASSESSMENT OF CHROMOSOMAL ALTERATIONS TO PREDICT CLINICAL OUTCOME OF BORTEZOMIB TREATMENT | MILLENNIUM PHARMACEUTICALS, INC. | 2016-10-27 | — | — | US | disclosed |
| US-20150240315-A1 | BIOMARKERS AND METHODS TO PREDICT RESPONSE TO INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-08-27 | — | — | US | disclosed |
| US-20150152502-A1 | BIOMARKERS OF RESPONSE TO PROTEASOME INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-06-04 | — | — | US | disclosed |
| US-20100086922-A1 | Assessment of chromosomal alterations to predict clinical outcome of bortezomib treatment | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150152502-A1 | BIOMARKERS OF RESPONSE TO PROTEASOME INHIBITORS | PSMB4, PSMB1, PSME3 | NTSR1 4259/4885PSMB5 14/4885LNPEP 3384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.